Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 104-109

  Mir, Olivier ^a   Boudou Rouquette, Pascaline ^a   Giroux, Julie ^a   Chapron, Jeanne ^a   Alexandre, Jérôme ^a   Gibault, Laure ^a   Ropert, Stanislas ^a   Coriat, Romain ^a   Durand, Jean Philippe ^a   Burgel, Pierre Régis ^a   Dusser, Daniel ^a   Goldwasser, François ^a  

^a Institut Cochin   (France)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Non small cell lung cancer; Oxaliplatin; Pemetrexed; VEGF A

Indexed keywords

BEVACIZUMAB; OXALIPLATIN; PEMETREXED;

ADULT; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861746936     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.01.014     Document Type: Article

References (37)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. D'Addario G., Fruh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
3. Baldwin C.M., Perry C.M. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. Drugs 2009, 69:2279-2302.
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
6. Scagliotti G.V., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005, 11:690-696.
7. Patel J.D., Hensing T.A., Rademaker A., Hart E.M., Blum M.G., Milton D.T., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27:3284-3289.
8. Heist R.S., Fidias P., Huberman M., Ardman B., Sequist L.V., Temel J.S., et al. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1153-1158.
9. Takimoto C.H., Graham M.A., Lockwood G., Ng C.M., Goetz A., Greenslade D., et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007, 13:4832-4839.
10. Mir O., Alexandre J., Ropert S., Amsellem-Ouazana D., Flam T., Beuzeboc P., et al. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 2005, 16:1017-1021.
11. Mir O., Alexandre J., Ropert S., Montheil V., Martin I., Durand J.P., et al. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anticancer Drugs 2009, 20:105-108.
12. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996, 52:1855-1865.
13. Faivre S., Le Chevalier T., Monnerat C., Lokiec F., Novello S., Taieb J., et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002, 13:1479-1489.
14. Reck M., Barlesi F., Crino L., Henschke C.I., Isla D., Stiebeler S., et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2011, (Epub ahead of print). 10.1093/annonc/mdr463.
15. Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16:269-278.
16. Durand J.P., Madelaine I., Scotte F. Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 2009, 96:951-960.
17. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008, 5:32-43.
18. Mir O., Alexandre J., Coriat R., Ropert S., Boudou-Rouquette P., Bui T., et al. Safety of bevacizumab 7.5mg/kg infusion over 10min in NSCLC patients. Invest New Drugs 2011, (Epub ahead of print). 10.1007/s10637-011-9690-9.
19. Caussanel J.P., Levi F., Brienza S., Misset J.L., Itzhaki M., Adam R., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82:1046-1050.
20. Mir O., Coriat R., Cabanes L., Ropert S., Billemont B., Alexandre J., et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011, 16:1325-1332.
21. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
22. Malhotra B., Evans T., Weiss J., Eaby B., Stonehouse-Lee S., Sherry V., et al. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Clin Lung Cancer 2010, 11:192-197.
23. Barlesi F., de Castro J., Dvornichenko V., Kim J.H., Pazzola A., Rittmeyer A., et al. AVAPERL (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (L) bev-cisplatin (cis)-pem treatment (Tx). Eur J Cancer 2011, 47:16.
24. Lee D.H., Choi C.M., Kim S.W., Suh C., Lee J.S. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. Med Oncol 2011, 10.1007/s12032-12011-19944-12036.
25. Loriot Y., Mordant P., Deutsch E., Olaussen K.A., Soria J.C. Are RAS mutations predictive markers of resistance to standard chemotherapy. Nat Rev Clin Oncol 2009, 6:528-534.
26. Raez L.E., Kobina S., Santos E.S. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2010, 11:18-24.
27. Kakolyris S., Ziras N., Vamvakas L., Varthalitis J., Papakotoulas P., Syrigos K., et al. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 2006, 54:347-352.
28. Monnet I., Brienza S., Hugret F., Voisin S., Gastiaburu J., Saltiel J.C., et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998, 34:1124-1127.
29. Lilenbaum R., Raez L., Tseng J., Seigel L., Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:511-515.
30. Monnet I., de C.H., Soulie P., Saltiel-Voisin S., Bekradda M., Saltiel J.C., et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 2002, 13:103-107.
31. Tredaniel J., Becht C., Bekradda M., De Cremoux H., Alexandre J., Chomy F., et al. An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer 2009, 63:259-263.
32. Bidoli P., Zilembo N., Cortinovis D., Mariani L., Isa L., Aitini E., et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007, 18:461-467.
33. Le Chevalier T., Breton J.L., Thezenas S., Coudert B., Sun X., Laza M., et al. Randomized phase II study of gemictabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC) - CLEO05. J Clin Oncol 2006, 24:7097.
34. Weissman C.H., Reynolds C.H., Neubauer M.A., Pritchard S., Kobina S., Asmar L. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:358-364.
35. Quoix E., Zalcman G., Oster J.P., Westeel V., Pichon E., Lavole A., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
36. Marx G.M., Blake G.M., Galani E., Steer C.B., Harper S.E., Adamson K.L., et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004, 15:291-295.
37. Beijers A.J., Jongen J.L., Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 2012, 70:18-25.